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Background: The value of adjuvant chemotherapy in colorectal cancer is well studied, and guidelines have been
established. Little is known about how treatment guidelines are implemented in the everyday clinical setting.
Methods: This national population-based study on nearly 34,000 patients with colorectal cancer evaluates the
adherence to present clinical guidelines for adjuvant chemotherapy. Virtually all patients with colorectal cancer
in Sweden during the years 2007–2012 and data from the Swedish Colorectal Cancer Registry were included.
Results: In colon cancer stage III, adherence to national guidelines was associated with lower age, presence of
multidisciplinary team (MDT) conference, low co-morbidity, and worse N stage. The MDT forum also affected
whether or not high-risk stage II colon cancer patients were considered for adjuvant chemotherapy. Rectal cancer patients
both in stage II and III were considered for adjuvant chemotherapy less often than colon cancer patients, but the same
factors influenced the decision. Adjuvant chemotherapy was started later than eight weeks after surgery in 30% of colon
cancer patients and in 38% of rectal cancer patients.
Conclusions: In Sweden, the adherence to national guidelines for adjuvant chemotherapy in colon cancer stage III is
acceptable in younger and healthier patients. MDT conferences are of major importance and affect whether patients are
recommended for adjuvant chemotherapy. Special consideration needs to be given to certain subgroups of patients,
particularly older patients and patients with poorly differentiated tumors. There is a need to shorten the waiting time until
start of chemotherapy.
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In Sweden, almost 6000 patients are diagnosed annually
with colorectal cancer (CRC), which is the third most
common cancer in the world [1]. Surgery offers the best
chance for curing CRC, but adjuvant chemotherapy can
further improve survival. While international and national
guidelines regarding indications for adjuvant chemother-
apy in CRC have been established, few population-based
studies have evaluated adherence to practice guidelines.
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unless otherwise stated.Sweden there are nationally accepted guidelines, which
are currently under revision [2]. Since 2008, the guidelines
have recommended that patients younger than 76 years of
age with stage III colon cancer should be considered for
six months of 5-FU-calciumfolinate or capecitabine alone
or in combination with oxaliplatin. High-risk stage II
colon cancer may be eligible for treatment, as in stage
III. Adjuvant chemotherapy is not recommended for
rectal cancer stage II or III.
The European Society for Medical Oncology (ESMO)
recently published guidelines for CRC [3-5]. These guide-
lines recommend adjuvant chemotherapy for high-risk
stage II and stage III colon cancer; although it is recog-
nized that there is less scientific evidence, it is also written
that patients with high-risk stage II and stage III rectalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer. However, at the 2013 European Registration of
Cancer Care (EURECCA) consensus conference, min-
imal or no consensus was reached regarding adjuvant
chemotherapy for rectal cancer [6]. The guidelines from
the American National Comprehensive Cancer Network
(NCCN) are consistent with the ESMO guidelines, but
they also include the possibility of adjuvant chemotherapy
for patients with low-risk stage II disease [7,8].
Some studies on adherence to clinical guidelines have
been conducted, including one large study from the
United States that presents a stage-dependent difference
in adherence in which high-risk stage II colon cancer had
the lowest correspondence [9]. Other studies have sug-
gested an association between older age and lower adher-
ence to guidelines, especially regarding the prescription of
oxaliplatin [10-13]. In contrast, one recent study found
high compliance levels in elderly patients; however, pa-
tients defined as elderly were younger than in the previ-
ously mentioned studies [14].
To obtain a population-based patient cohort is difficult,
and when selected centers or local regions with low cover-
age of the population are used, there is a risk of selection
bias. Sweden has the unique opportunity of performing
truly national population-based studies; nearly all patients
with CRC are included in a quality control registry. The
main purposes of the registry are to audit management
and outcome, report data for quality improvements, and
provide valid data for research. The aim of this study was
to evaluate adherence to national guidelines on adjuvant
chemotherapy.Methods
Data and cohort construction
The Swedish Colorectal Cancer Registry (SCRCR) cap-
tures at least 99% of all patients diagnosed with CRC in
Sweden [15,16]. The registry has been validated against
medical records for a full-year cohort, showing 94–97%
agreement on six variables, and a study on the validity of
the registry’s first three years deemed it as “good” [17].
The inclusion criterion for this study was patients reg-
istered in the SCRCR from 1 January 2007 to 31 December
2012, and the primary outcome of interest was planned
adjuvant chemotherapy. Patients in stage II or III are eli-
gible for adjuvant chemotherapy in different guidelines;
thus, patients with stage I or IV or with no stage listed
were excluded. In addition, patients who underwent
local excision or who had no surgical resection were ex-
cluded in order to ensure a true stage classification. Since
2009, the department responsible for oncological treat-
ment has also reported data on started chemo- and radio-
therapy; therefore, the secondary outcome of interest was
started adjuvant chemotherapy. Data on patients withrecords from 1 January 2009 to 31 December 2012 were
then obtained from the oncology database.
A total of 1086 patients had two or more registered oc-
currences of CRC, which were counted as one. Patients
were restaged according to the 7th edition of the tumor
node metastasis (TNM) staging system of the International
Union against Cancer/American Joint Committee on
Cancer using pathological data of the number of positive
lymph nodes. Tumor deposits or satellites in the lymph
drainage area of pericolorectal adipose tissue are classified
as N1c according to the 7th edition; however, they were
not recorded in the SCRCR before 2011 and are disre-
garded here and classified as N0. Histological grading was
regarded according to the new dichotomized scale: low
grade (G1–G2) and high grade (G3–G4). Patients with
stage II disease were subgrouped according to high or low
risk. Patients included in the high-risk population were
those with an emergency intestinal occlusion or perfor-
ation, lymph node sampling less than 12, T4 tumor, poorly
differentiated tumor (G3–G4), and vascular or perineural
invasion. However, lymphatic invasion is not reported in
the SCRCR, and information about vascular and perineu-
ral invasion is sometimes lacking in the pathology report.
This study was approved by the regional ethical review
board in Gothenburg, (Decision Number 072-13). The data
analysed in this study are not publicly accessible. After ap-
proval from the regional ethical review board, permission
was granted from the steering group of the SCRCR for ex-
traction of registry-data. The SCRCR data-set is continu-
ously updated and data for this study was extracted on
May 24th 2013.
Statistical analyses
The data were summarized using contingency tables. All
analyses were conducted separately for colon cancer and
rectal cancer. For the subgroup of patients with stage III
colon cancer, univariate logistic regression was applied to
assess the putative relation of classical risk factors on the
outcome, quantified in terms of 95% confidence intervals.
In order to adjust for possible confounding, the resulting
factors of interest were included in a multivariate logistic
regression analysis. First-level interactions of gender and
age against all other covariates were each entered into the
model separately; none was found to be significant. Good-
ness of fit of the final model was assessed using the
Hosmer–Lemeshow chi-square statistics [18]. Confidence
intervals and Wald tests were used to evaluate significance
in the multivariate analyses.
All analyses were carried out using the R 2.15.1
software [19].
Results
During the six-year period, 33,944 patients were included
in the SCRCR, of which17,521 were in stage II or III
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years of age and were excluded from selected analyses.
The demographics and characteristics of the patients
are reported in Table 1. Of the 10,459 patients younger
than 76 years of age, 5297 (50.6%) were planned for ad-
juvant chemotherapy.Colon cancer stage III
Guidelines recommend adjuvant chemotherapy in colon
cancer stage III, and of 3485 patients younger than 76
years of age, 2922 (83.8%) were planned for this treatment
(Figure 1). Factors associated with treatment were age
(p < 0.01), comorbidity (p < 0.01), and N stage (p < 0.01)
(Table 2). Discussing patients in an MDT conference (p <
0.01) also affected whether adjuvant chemotherapy was
planned; it was planned in 81.7% of patients younger than
76 years of age, ASA 1-2, who were not discussed and in
90.6% in patients who were discussed. Patients younger
than 60 years of age were evaluated in MDT conferences
in 82.4% of the cases, as were 79.4% of patients 60–75
years of age and 68.4% of patients older than 75 years of
age. Further subgroup analyses are presented in Additional
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Figure 1 Flow chart of the study. Abbreviation: CT = chemotherapy. *
perforation, lymph nodes sampling <12, pT4, poorly differentiated tumour
excision (n = 334), no surgery (n = 1243), surgery (n = 2224) and missing (nColon cancer stage II
As discussed in the background section, patients in stage
II also may be recommended adjuvant chemotherapy.
Colon cancer stage II patients younger than 76 years of age
were planned for adjuvant chemotherapy in 789 (21.8%) of
the cases; of those 722 (91.5%) were high risk and 67
(8.5%) were low risk (Figure 1). There was an increase in
patients planned for adjuvant chemotherapy over time
(Figure 2). Patients meeting at least one high-risk criterion
and not planned for adjuvant chemotherapy numbered
1159 (Figure 1). The proportion of high-risk patients con-
sidered for adjuvant chemotherapy was lower at older
ages, in the presence of comorbidity, and in the absence of
an MDTconference (Additional file 1: Table S1).
Of the high-risk stage II patients, 33.3% met more than
one high-risk criterion. There was a high proportion of pa-
tients planned for adjuvant chemotherapy among patients
with the high-risk criterion pT4 (63.5%) and almost half of
the patients were planned for chemotherapy if vascular or
perineural invasion was present (Table 3).
Rectal cancer stage II-III
Of 1843 patients with stage III rectal cancer, 1306 (70.9%)
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≤75 7107 (55.8) 3352 (69.9) 10459 (59.7)
>75 5616 (44.1) 1443 (30.1) 7059 (40.3)
Missing data 3 (0.0) - 3 (0.0)
Gender (%)
Male 6179 (48.6) 2854 (59.5) 9033 (51.6)
Female 6547 (51.4) 1941 (40.5) 8488 (48.4)
Elective surgery (%)
Yes 10306 (81.0) 4731 (98.7) 15037 (85.8)
No 2419 (19.0) 60 (1.3) 2479 (14.1)
Missing data 1 (0.0) 4 (0.1) 5 (0.0)
Stage* (%)
II (T3, T4, N0) 6842 (53.8) 2211 (46.1) 9053 (51.7)
III (Any T, N1, N2) 5884 (46.2) 2584 (53.9) 8468 (48.3)
Mucinous (%)
Yes 2583 (20.3) 651 (13.6) 3234 (18.5)
No 8863 (69.6) 3593 (74.9) 12456 (71.1)
Missing data 1280 (10.0) 551 (11.5) 1831 (10.0)
Examined lymph nodes (%)
<12 1936 (15.2) 1171 (24.4) 3107 (17.7)
≥12 10644 (83.6) 3571 (74.5) 14215 (81.1)
Missing data 146 (1.1) 53 (1.1) 199 (1.1)
Tumor differentiation* (%)
Low grade (G1, G2) 9268 (72.8) 3830 (79.9) 13098 (74.8)
High grade (G3, G4) 3004 (23.6) 746 (15.6) 3750 (21.4)
Not indicated 390 (3.1) 193 (4.0) 583 (3.3)
Missing data 64 (0.5) 26 (0.5) 90 (0.5)
ASA† (%)
1 1842 (14.5) 1002 (20.9) 2844 (16.2)
2 6443 (50.6) 2620 (54.6) 9063 (51.7)
3 3719 (29.2) 1010 (21.1) 4729 (27.0)
4 362 (2.8) 66 (1.4) 428 (2.4)
5 4 (0.0) 0 (0.0) 4 (0.0)
Missing data 356 (2.8) 97 (2.0) 453 (2.6)
Region of treatment (%)
Northern 1164 (9.1) 444 (9.3) 1608 (9.2)
Uppsala/Örebro 2873 (22.6) 1110 (23.1) 3983 (22.7)
Stockholm/Gotland 2380 (18.7) 868 (18.1) 3248 (18.5)
Western 2311 (18.2) 909 (19.0) 3220 (18.4)
Table 1 Demographics and clinical characteristics
(Continued)
South-eastern 1533 (12.0) 558 (11.6) 2091 (11.9)
Southern 2464 (19.4) 906 (18.9) 3370 (19.2)
Missing data 1 (0.0) - 1 (0.0)
Stage II-III colorectal cancer patients operated with resection of the tumor
during 2007 to 2012. Data from the Swedish colorectal cancer registry.
*TNM, 7th edition from UICC/AJCC (Union for International Cancer Control/
American Joint Committee on Cancert). †American Society of Anesthesiologists
Physical Status Classification System.
Table 2 Patients planned for adjuvant chemotherapy,
younger than 76 years with stage III colon cancer by
patient and health-care region (n = 3427)
Univariate Multivariate
OR 95% CI OR 95% CI P‡
Gender
Male 1.00 1.00
Female 1.36 1.13-1.65 1.29 1.04-1.61 0.021
Age (years)
60-75 1.00 1.00
<60 2.65 2.02-3.55 2.14 1.57-2.98 <0.01
ASA classification*
3-4 1.00 1.00
1-2 4.31 3.51-5.28 4.26 3.14-5.33 <0.01
N-stage†
1a 1.00 1.00
1b 1.29 1.01-1.66 1.20 0.92-1.57
2 1.64 1.29-2.08 1.62 1.24-2.12 <0.01
Tumor differentiation†
Low-grade (G1, G2) 1.00 1.00
High-grade (G3, G4) 0.94 0.76-1.17 0.84 0.66-1.08 0.17
Planned surgery
Yes 1.00 1.00
No 0.79 0.63-0.99 0.83 0.64-1.09 0.18
Multidisciplinary conference
No 1.00 1.00
Yes 1.78 1.44-2.21 1.83 1.41-2.37 <0.01
Region
Northern 1.00 1.00
Stockholm-Gotland 1.29 0.89-1.84 0.96 0.63-1.46
Uppsala-Örebro 1.45 1.02-2.05 1.14 0.75-1.71
Southeastern 1.10 0.74-1.63 0.89 0.56-1.40
Southern 1.33 0.92-1.89 1.17 0.76-1.79
Western 1.16 0.82-1.64 0.95 0.63-1.42 0.67
Complete case univariate and multivariate logistic regression.
Abbreviation: OR, Odds Ratio. *American Society of Anesthesiologists Physical
Status Classification System. †TNM, 7th edition from UICC/AJCC (Union for
International Cancer Control/American Joint Committee on Cancert).
‡Statistical method; Wald test.
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Figure 2 Proportion of patients where adjuvant chemotherapy was planned per year for each combination of stage and site (n = 16 690).
Stratified multivariate analyses where year is entered as a continuous covariate in a model, which also adjusts for age, and sex indicate an increasing
trend for adjuvant chemotherapy in all four groups (p < 0.05).
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cer. These proportions were lower compared to colon can-
cer (Figure 1). The proportions of patients considered for
adjuvant chemotherapy increased from 2007 to 2012 in
both stage II and III (Figure 2).
As in colon cancer the highest proportion of patients
in stage II with a high-risk criterion planned for adjuvant
chemotherapy was seen among patients with a pT4 tumor
(45.6%, Table 3).Table 3 Stage II, colon and rectal cancer, younger than 76 ye
Colon
Planned CT
Total number of patients 663
pT4 363 (63.5)
N (%)
Poorly differentiated 201 (32.7)
N (%)
Vascular invasion 187 (48.4)
N (%)
Intestinal occlusion 127 (33.7)
N (%)
Lymph node sampling <12, N (%) 116 (27.2)
Perineural invasion 90 (45.9)
N (%)
Intestinal perforation 27 (37.5)
N (%)
More than one criterion can apply for each patient.
Abbreviation: CT, Chemotherapy.Oncology dataset 2009–2012
Of 4272 patients with CRC planned for adjuvant chemo-
therapy between 2009 and 2012, oncology data was re-
ported in 3985 (93.3%) cases. In colon cancer, adjuvant
chemotherapy was started in 91.8% (n = 2812) of resected
patients planned for adjuvant chemotherapy. The corre-
sponding figure for rectal cancer was 76.6% (n = 1173).
Where oncology data indicated chemotherapy for a colon
cancer (n = 2595), 5-FU or capecitabine was prescribed as aars – risk factors and planned adjuvant chemotherapy
Rectum
No CT Planned CT No CT
1159 204 549
209 (36.5) 57 (45.6) 68 (54.4)
414 (67.3) 49 (29.3) 118 (70.7)
199 (51.6) 73 (32.6) 151 (67.4)
250 (66.3) 2 (33.3) 4 (66.7)
310 (72.8) 85 (23.2) 281 (76.8)
106 (54.1) 60 (37.7) 99 (62.3)
45 (62.5) 24 (37.5) 40 (62.5)
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III N1, and in 30.9% of stage III N2 cases (Table 4). A com-
bination with oxaliplatin was prescribed at highest propor-
tion to stage III N2 (63.3%) and N1 (48.6%), see Table 4.
The proportion of patients treated with oxaliplatin was age
dependent, and in stage III N2 82.9% of patients younger
than 70 years received the combination with oxaliplatin,
compared to 63.5% if stage III N1. Adjuvant chemotherapy
was started within six weeks of surgery in 18.2% of the
cases, more than eight weeks after surgery in 30.1%, and
more than 12 weeks after surgery in 4.1%.
Of the 922 patients with rectal cancer who received
adjuvant chemotherapy, 239 patients had received pre-
operative chemotherapy. Of those patients, 211 (88.3%)
received long-course radiotherapy, and 123 (51.5%) had
a primarily unresectable tumor. In comparison, among
the 1560 patients with rectal cancer who did not receive
adjuvant chemotherapy, 248 patients received preopera-
tive long-course chemoradiation, and 121 had a primarily
unresectable tumor. Thus, 211 (46.0%) of 459 patients who
received preoperative chemoradiation started adjuvant
chemotherapy postoperatively. Short-course radiotherapy
(5x5Gy) was given to 1997 patients, 522 (26.1%) of these
received adjuvant chemotherapy. 5-FU or capecitabine
alone was prescribed to more than half of the cases in
stage II and stage III N1 and in 35.7% of the cases in stage
III N2. As in colon cancer, combination treatment was
prescribed in highest proportion to stage III N2 (52.0%),
see Table 4. Adjuvant chemotherapy was started within six
weeks of surgery in 16.9% of the cases, more than eight
weeks after surgery in 37.0%, and more than 12 weeks
after surgery in 4.7%.
Discussion
In this population-based dataset covering over 99% of
patients diagnosed with CRC in Sweden, the adherence
to national guidelines for adjuvant chemotherapy in colonTable 4 Started postoperative chemotherapy stage II-III
Stage II
Low risk (%) H
Colon cancer 107 53
Capecitabine/5-FU 51 (47.7) 29
Capecitabine/5-FU+ 42 (39.2) 20
Oxaliplatin
Other combinations 14 (13.1) 34
Rectal cancer 135 25
Capecitabine/5-FU 72 (53.3) 14
Capecitabine/5-FU+ 33 (24.4) 66
Oxaliplatin
Other combinations 28 (20.7) 50
Abbreviation: 5-FU, 5-fluorouracil.cancer stage III was high in younger and healthier pa-
tients. However, the adherence was considerably lower in
some subgroups of patients.
In recent years, with a multimodal approach to CRC
treatment, the importance of MDT conferences has in-
creased [6]. In this study, patients with both high-risk
stage II and stage III colon cancer were planned for ad-
juvant chemotherapy considerably more often when they
were discussed in a postoperative MDT conference (stage
III, p < 0.01, see Table 2). There was an age-dependent dif-
ference in the proportion of patients brought up at MDT
conferences, indicating a tendency toward leaving out
MDT conferences in the elderly and comorbid popula-
tions. However, the differences persisted after correction
for age, comorbidities, and N-stage. The impact of MDT
conferences affecting the proportion of patients receiving
adjuvant chemotherapy is supported by other studies, and
some studies also show a correlation between MDT and
better survival [20,21].
Nodal stage is the main factor determining whether
guidelines recommend adjuvant chemotherapy for CRC
patients. As a prognostic factor, the number of positive
lymph nodes is important in both colon and rectal cancer
in stage III [22]. This is reflected in adherence to guide-
lines, with an increased proportion of patients with a more
advanced N stage being recommended for chemotherapy
(Table 2). In contrast, tumor differentiation, which is a
stage-independent prognostic factor in CRC, does not
affect whether patients are planned for adjuvant chemo-
therapy [23,24]. Emergency surgery did not either affect
whether patients were planned for adjuvant chemother-
apy, even though this is one of the high-risk factors and an
association with worse cancer-specific long-term survival
has been shown in several studies [15,25].
Presence of comorbidities was another main factor in-
fluencing whether patients were planned for adjuvant
chemotherapy, and patients with ASA 1–2 were four timesStage III
igh risk (%) N1 (%) N2 (%)
9 1425 1088
6 (54.9) 662 (46.4) 336 (30.9)
9 (38.8) 693 (48.6) 689(63.3)
(6.3) 70 (4.9) 63 (5.8)
8 556 471
2 (55.0) 294 (52.9) 168 (35.7)
(25.6) 203 (36.5) 245 (52.0)
(19.4) 59 (10.6) 58 (12.3)
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tients with ASA 3–4. Age was another factor influencing
adjuvant chemotherapy. Even when corrected for comor-
bidities included in the ASA classification, patients younger
than 60 years of age were planned for chemotherapy more
than twice as often as patients 60–75 years of age. Our
results are consistent with the results of other registry
studies, which also reported lower adherence to treatment
guidelines in older patients, independent of pre-existing
comorbidities [9,12,26].
Swedish guidelines do not recommend adjuvant chemo-
therapy for rectal cancer. However, adjuvant chemother-
apy was planned in about 70% of patients with stage III
rectal cancer, and it was started in three out of four pa-
tients (2009–2012). The data show an overtreatment in re-
gard to national guidelines that increased over time and
likely reflect that many physicians follow international
guidelines. However, adjuvant chemotherapy for rectal
cancer is an extremely controversial issue due to the lack
of clear evidence from randomized trials [27-30]. Its use is
particularly controversial in patients who have had pre-
operative chemoradiotherapy; in addition to the EORTC
22921 study, three other European randomized trials
have not been able to detect a significant survival gain
[27,31-33]. It is presently an open question what the up-
dated Swedish guidelines will recommend. It is possible
that rectal cancers should not be handled homogeneously;
rectal tumors in the upper intraperitoneal third could be
handled as colon cancers, as opposed to tumors arising
extraperitoneally [34]. In light of this lack of scientific
knowledge, it is surprising that approximately half of
patients who received preoperative chemoradiotherapy
because of a locally advanced tumor continued with post-
operative adjuvant therapy. The international guidelines,
along with a belief that it should work, have had a great
impact [3-5,7,8].
Most patients with rectal cancer who received preopera-
tive chemoradiation therapy had locally advanced tumors.
Therefore, the main reason to start chemotherapy pre-
operatively was probably to potentiate the radiotherapy
effect, in which case capecitabine alone is presently used.
The concept of providing adequate systemic therapy
upfront is currently being explored in trials [27,35].
In colon cancer stage III the combination of 5-FU with
oxaliplatin is associated with better disease-free survival
and overall survival [36-38]. However, the oxaliplatin
combination-therapy is associated with more side effects
and might not be applicable to all patients [38]. The num-
ber of patients treated with combination-therapy might be
considered low (Table 4), it was however age-dependent
and in patients younger than 70 the proportion of patients
prescribed a combination-therapy was considerably higher.
Timing of chemotherapy is another topic of discussion.
Studies have shown value in an early start of adjuvantchemotherapy; starting chemotherapy later than 12 weeks
after surgery is of questionable value, although some stud-
ies have indicated a survival benefit even with a late start.
[39,40] In the Swedish guidelines, there are no specific
recommendations for the timing of adjuvant chemother-
apy; however, several regions recommend that every effort
should be made to start as early as possible, and no later
than eight weeks. There is no scientific rationale for eight
weeks, but it should be remembered that all colon cancer
trials that have shown a significant survival gain required
that therapy should start within 5–6 weeks. The European
guidelines recommend as early a start as possible, from
the third week up to a maximum of 8–12 weeks after sur-
gery. In the present study cohort, one-third of the patients
started their adjuvant chemotherapy later than eight weeks
postoperatively.
The benefit from adjuvant chemotherapy on a group
level and the absolute risk reduction of developing meta-
static disease is lower in stage II than in stage III cancer.
To better identify patients who might benefit from chemo-
therapy in stage II, patients need to be separated into high-
and low-risk groups. ESMO and NCCN guidelines now
recommend adjuvant chemotherapy for high-risk stage II
cancer. In this study, there was an increase over time in
the proportion of patients with stage II disease consid-
ered for chemotherapy in both rectal and colon cancer
(Figure 2). Still there was a large portion of patients not
considered for adjuvant chemotherapy even though one
or several high-risk criteria were fulfilled. As mentioned
previously, conducting an MDT conference is one of
the main factors influencing whether patients with stage II
are planned for adjuvant chemotherapy. However, with
improved surgical techniques and pathological examina-
tions of surgical specimens, stage migration is a likely fac-
tor affecting changes to a better prognosis in stages II and
III [41]. Thus, re-evaluation of some of the high-risk cri-
teria in stage II is an important topic.
This study has several limitations. The data were not
consistently validated, and information bias is a possibil-
ity. However, previous validations showed fair agreement
with medical records, and we have no reason to believe
this has changed. Most of our statistical calculations were
carried out on data for planned chemotherapy and some
were carried out on initiated treatment. Unfortunately, the
SCRCR does not collect data on duration or compliance
of chemotherapy regimens. The main strengths of the
study are the sheer size and the fact that it is based on the
entire Swedish population, and therefore, truly population
based. Another strength is the ability to account for miss-
ing data.
Conclusions
Although the general adherence levels to present national
practice guidelines are acceptable in some aspects, all
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this factor seems to affect the proportion of patients
considered for adjuvant chemotherapy, even in cases
without significant comorbidities. Special consideration
should be given to patients over the age of 60 and to pa-
tients with poorly differentiated tumors.
To possibly improve the outcome of, or at least make
the best of, a given treatment, the time until the begin-
ning of the therapy needs to be reduced. It has been hy-
pothesized that an important reason for lack of a clear
benefit in rectal as opposed to colon cancer is the inability
to initiate the adjuvant chemotherapy early enough [42].
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